Scholars in Health Research Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
Department of Internal Medicine, Division of Endocrinology, Calcium Metabolism and Osteoporosis Program, Beirut, Lebanon.
J Clin Endocrinol Metab. 2021 Jan 23;106(2):e990-e1001. doi: 10.1210/clinem/dgaa780.
Questions regarding the superiority of free and bioavailable 25-hydroxyvitamin D [25(OH)D] in predicting health outcomes remain unresolved.
This study investigates the impact of vitamin D variables-total, bioavailable, or free 25(OH)D-on indices of bone and mineral metabolism, at baseline and in response to 2 vitamin D doses.
Our objectives are implemented as exploratory analyses on data collected in a 1-year, double-blind, randomized controlled trial completed in July 2014.
Participants were recruited from 3 major hospitals in an ambulatory setting.
Participants were >65 years of age, overweight, and had a baseline serum 25(OH)D between 10 and 30 ng/mL. A total of 221 participants completed the study.
Subjects were randomized to receive calcium and oral vitamin D3 (600 IU/day or 3750 IU/day) supplementation.
Participants who received the higher vitamin D dose had levels that were 1.3- to 1.4-fold higher than those taking the lower dose, for all variables (P value < 0.001). Serum values of bioavailable and free 25(OH)D were associated with total 25(OH)D, with r values of 0.942 and 0.943, respectively (P value < 0.001). Parathyroid hormone (PTH) was negatively associated with all vitamin D variables, with correlation coefficients ranging from -0.22 to -0.25, while calcium and bone turnover markers (carboxy-terminal collagen crosslinks and osteocalcin) did not. Only total 25(OH)D had a positive relationship with % change bone mineral density (BMD) at the femoral neck at 12 months, while only free and bioavailable 25(OH) had a positive relationship with % change total body BMD at 12 months.
Calculated free and bioavailable 25(OH)D do not appear to be superior to total 25(OH)D in predicting indices of bone health in an elderly population.
关于游离和生物可利用 25-羟维生素 D [25(OH)D]在预测健康结果方面的优势的问题仍未得到解决。
本研究调查了维生素 D 变量(总、生物可利用或游离 25(OH)D)在基线和对 2 种维生素 D 剂量的反应时对骨和矿物质代谢指标的影响。
我们的目标是在 2014 年 7 月完成的为期 1 年、双盲、随机对照试验的数据中进行探索性分析。
参与者是在门诊环境中从 3 家大医院招募的。
参与者年龄大于 65 岁,超重,基线血清 25(OH)D 在 10 至 30ng/mL 之间。共有 221 名参与者完成了研究。
受试者随机接受钙和口服维生素 D3(600IU/天或 3750IU/天)补充。
接受较高维生素 D 剂量的参与者的所有变量(P 值均<0.001)水平比接受较低剂量的参与者高 1.3-1.4 倍。生物可利用和游离 25(OH)D 的血清值与总 25(OH)D 相关,r 值分别为 0.942 和 0.943(P 值均<0.001)。甲状旁腺激素(PTH)与所有维生素 D 变量呈负相关,相关系数范围为-0.22 至-0.25,而钙和骨转换标志物(羧基末端胶原蛋白交联和骨钙素)则没有。只有总 25(OH)D 与 12 个月时股骨颈的骨密度(BMD)百分比变化呈正相关,而游离和生物可利用的 25(OH)D 仅与 12 个月时全身 BMD 的百分比变化呈正相关。
在老年人群中,计算的游离和生物可利用 25(OH)D 似乎并不优于总 25(OH)D 来预测骨健康指标。